<DOC>
	<DOCNO>NCT02882230</DOCNO>
	<brief_summary>The frequency neurological psychiatric complaint participant take rilpivirine , elvitegravir , dolutegravir reach average 20â€”30 % clinical trial . The inclusion exclusion criterion enrol people live HIV time selective subsequent description minor severe adverse event ( AE 's ) often imprecise ambiguous one extrapolate particular research result practice medicine . These adverse event negatively affect patient 's quality life ultimately good adherence treatment . This study aim assess prevalence describe neurological psychiatric adverse event related drug .</brief_summary>
	<brief_title>Evaluation Neurologic Psychiatric Adverse Events Several Antiretroviral Drugs Real Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>HIV infection age &gt; 18 treatment rilpivirine , elvitegravir , dolutegravir ( exposed patient ) treatment none drug ( non expose patient ) capacity read French language drug addiction ( except amyl nitrile ( `` popper '' ) cannabis ) alcoholism coinfection hepatitis C virus pregnant breast feeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>